Drug Search Results
More Filters [+]

TPM-1116

Alternative Names: TPM-1116, TPM1116, TPM 1116
Latest Update: 2024-05-01
Latest Update Note: Clinical Trial Update

Product Description

A highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile. (Sourced from: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-announces-exclusive-agreement-develop-and)

Mechanisms of Action: OX2R Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Harmony Biosciences, LLC
Company Location: PLYMOUTH MEETING PA 19462
Company CEO: John C. Jacobs
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TPM-1116

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Narcolepsy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title